Despite substantial progress in the past two decades, cancer remains the leading cause of death by disease in US children between 1 and 15 years of age. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and cure rates are approaching ~ 80% today. Unfortunately, 20% of children with ALL are not cured with current therapy, making the number of cases of relapsed ALL greater than the total number of new cases of most childhood cancers. Previous work has established that de novo drug resistance is a primary cause of treatment failure in childhood ALL. However, the genomic determinants of drug resistance remain poorly defined. The research supported by this MERIT award has focused on elucidating the genomic determinants of inter-patient differences in drug response in children with ALL, leading to a number of new insights into the pharmacogenomics of childhood ALL. Our scientific aims are focused on some of the most widely used antileukemic agents, thiopurines and glucocorticoids (with complementary studies of L- asparaginase and vincristine).
The first aim i s to identify genes that influence the response to thiopurines (mercaptopurine, thioguanine), using genomewide approaches for gene expression analyses of ALL cells, and SNP analyses of germline and ALL cell DNA to identify SNPs and copy number variations (CNVs) that are significantly related to drug sensitivity and response. Studies in Aim 2 are designed to elucidate these pharmacogenomic traits in T-ALL, a less common subtype that is more resistant to curative chemotherapy, and compare these findings to B-lineage ALL. Once we identify these genes or genome abnormalities (SNPs, CNVs) influencing ALL drug resistance and treatment response, we perform biochemical and genomic studies to determine the mechanism by which these genes or their variants influence the sensitivity of ALL cells to these chemotherapeutic agents. In the continuation of this research program, we are extending our findings from the last 4 years of funding by exploiting new genomewide strategies to identify genomic determinants of drug response (e.g., 1 million SNP arrays, gene expression arrays, mIRNA arrays), to determine whether CNVs or specific mlRNAs modify the expression of genes and thereby alter the sensitivity of ALL cells to these chemotherapeutic agents. Our preliminary findings have indeed revealed specific mlRNAs that influence the sensitivity of ALL cells to these agents, and we have also recently discovered that specific CNVs in ALL cells can significantly influence drug resistance. The continuation of these studies will provide important new insights into the genomic determinants of treatment failure and point to novel targets for developing strategies to overcome drug resistance in childhood ALL.

Public Health Relevance

Pharmacogenomics has great potential to improve public health by minimizing drug-induced side events and improving treatment effectiveness. Acute lymphoblastic leukemia (ALL) the most common cancer in children, serves as a paradigm for a chemotherapy-sensitive malignancy. By capitalizing on the genomic studies which we have already conducted in children with ALL, and exploiting new genomewide technologies, we will define genomic polymorphisms that can be used to design less toxic and more efficacious cancer treatment regimens.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Method to Extend Research in Time (MERIT) Award (R37)
Project #
Application #
Study Section
Special Emphasis Panel (NSS)
Program Officer
Wu, Roy S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Liu, Y; Fernandez, C A; Smith, C et al. (2017) Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. Clin Pharmacol Ther :
Pui, Ching-Hon; Roberts, Kathryn G; Yang, Jun J et al. (2017) Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 17:464-470
Karol, S E; Larsen, E; Cheng, C et al. (2017) Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. Leukemia 31:1325-1332
Landier, Wendy; Hageman, Lindsey; Chen, Yanjun et al. (2017) Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. J Clin Oncol 35:1730-1736
Liu, C; Yang, W; Pei, D et al. (2017) Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther 101:373-381
Mapes, Brandon; El Charif, Omar; Al-Sawwaf, Shereen et al. (2017) Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res 23:4010-4019
Pui, C-H; Pei, D; Raimondi, S C et al. (2017) Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia 31:333-339
Campana, Dario; Pui, Ching-Hon (2017) Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood 129:1913-1918
Diouf, Barthelemy; Devaraju, Prakash; Janke, Laura J et al. (2016) Msh2 deficiency leads to dysmyelination of the corpus callosum, impaired locomotion, and altered sensory function in mice. Sci Rep 6:30757
Karol, Seth E; Mattano Jr, Leonard A; Yang, Wenjian et al. (2016) Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood 127:558-64

Showing the most recent 10 out of 250 publications